STUDY

Spironolactone beat doxycycline for adult women's acne

“Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.” Dréno B et al. Acta dermato-venereologica. February 2024

Dréno B et al. · Acta dermato-venereologica · February 2024

Randomized controlled trial
The finding

In adult women with moderate acne, six months of spironolactone led to more treatment successes than a three-month doxycycline course.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. Both groups also used 5% benzoyl peroxide. The doxycycline group switched to placebo capsules after month three.
At a glance

Who was studied and for how long

Randomized
133 women
Moderate adult acne
Comparison
6 months
Doxycycline stopped at month 3
Shared treatment
5% benzoyl peroxide
Both groups
Primary measure
Acne score
Checked at months 4 and 6
What they did

How the study worked

133 womenmoderate acneRANDOMSPLITSpironolactone65 assigned150 mg daily for 6 monthsDoxycycline68 assigned100 mg daily for 3 monthsMEASURED ATMonths 4 and 6acne score133 womenmoderate acneRANDOMSPLITSpironolactone65 assigned · 150 mg daily for 6 monthsDoxycycline68 assigned · 100 mg daily for 3 monthsMEASURED ATMonths 4 and 6acne score
Random assignment65 women were assigned spironolactone and 68 doxycycline.
TreatmentSpironolactone 150 mg daily continued for six months. Doxycycline 100 mg daily was given for three months, followed by three months of placebo.
AssessmentResearchers scored acne at months four and six.
What they found

The results

SpironolactoneDoxycycline

Treatment success at the better of two visits

This analysis used each participant’s better result at month 4 or 6. Both groups used benzoyl peroxide.

Spironolactone regimen
62%
Doxycycline regimen
32%
p = 0.0013
At month six, the odds of treatment success were 2.87 times as high with the spironolactone regimen (95% CI 1.38 to 5.99, p = 0.007). The month-four difference was uncertain (p = 0.579). The odds ratio is a separate estimate from the percentages above.
Who paid for it

Funding and conflicts of interest

The authors declared no conflicts of interest.

How much to trust it

Strengths and limits

Strengths

  • Double-blind randomized comparison
  • Both groups received the same topical treatment
  • Measured lesion counts and acne scores over time

Limits

  • Doxycycline stopped three months before the six-month assessment
  • The trial recruited fewer participants than planned
  • Only adult women with moderate acne were studied
Moderate confidence. The trial was double-blind, but it recruited fewer participants than planned and compared regimens with different treatment durations.
What it means for you

The takeaway

Regimen and timing matter

Six months of spironolactone plus benzoyl peroxide performed better by month six than a three-month doxycycline course with continued benzoyl peroxide.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

AFAST

An acne severity score for the face and under the jaw in adult women.

Odds ratio

A comparison of the odds of an outcome between groups. It differs from a ratio of percentages.

Original source

Dréno B, Nguyen JM, Hainaut E, Machet L, Leccia MT, Beneton N, Claudel JP, Célérier P, Le Moigne M, Le Naour S, Vrignaud F, Poinas A, Dert C, Boisrobert A, Flet L, Korner S, Khammari A. Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study.. Acta Derm Venereol. 2024;104:adv26002.

PMID 38380975